Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma
Brief Summary: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence.

PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone.


Options:
A: Arm Label: Arm I (radiation therapy, temozolomide, placebo); Type: ACTIVE_COMPARATOR; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Temozolomide | Arm Label: Arm II (radiation therapy, temozolomide, bevacizumab); Type: EXPERIMENTAL; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Biological: Bevacizumab, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Temozolomide | Intervention Type: RADIATION; Name: 3-Dimensional Conformal Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: RADIATION; Name: Intensity-Modulated Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: cognitive assessment; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm 1, Arm 2
C: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy

Answer: B